New Additions to Drugs.com for 2023
The following 51 drugs were added to the Drugs.com database in 2023.
Casgevy
Dec 10, 2023 - Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous suspension to treat adults and children aged 12 years and older who have sickle cell disease with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT).
Ogsiveo
Nov 28, 2023 - Ogsiveo (nirogacestat) is an oral, selective, gamma-secretase inhibitor that may be used to treat adults with progressing desmoid tumors who require systemic treatment.
DefenCath
Nov 15, 2023 - DefenCath is a combination catheter lock solution (CLS) containing taurolidine and heparin that may be used to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC).
Adzynma
Nov 12, 2023 - Adzynma (ADAMTS13, recombinant-krhn) is a human recombinant protein that may be used to prevent or treat blood clots by replacing missing or defective ADAMTS13 enzyme in adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). It is given by a healthcare provider as a slow intravenous (into the vein) infusion.
Zituvimet
Nov 7, 2023 - Zituvimet is an oral combination treatment containing sitagliptin and metformin that may be used to lower blood glucose (sugar) in adults with type 2 diabetes alongside diet and exercise.
Voquezna
Nov 2, 2023 - Voquezna (vonoprazan) is an oral potassium-competitive, acid blocker that may be used to block acid production in the stomach and is approved for heartburn associated with erosive esophagitis, healing of all grades of erosive esophagitis, and the treatment of Helicobacter pylori (H. pylori) infection in adults in combination with certain antibiotics.
Combogesic IV
Nov 1, 2023 - Combogesic IV is a prescription pain medication for adults that contains acetaminophen and ibuprofen, which may be given when an intravenous route of administration is considered clinically necessary to relieve mild to moderate pain or manage moderate to severe pain in addition to opioid analgesics.
Omvoh
Oct 29, 2023 - Omvoh (mirikizumab-mrkz) is an interleukin-23 antagonist that may be used to treat adults with moderately to severely active ulcerative colitis which is given by injection either into a vein (intravenously) or under the skin (subcutaneously).
Zymfentra
Oct 24, 2023 - Zymfentra (infliximab-dyyb) is a tumor necrosis factor (TNF) blocker that may be used to treat moderately to severely active Crohn’s disease or ulcerative colitis following induction therapy with an IV infliximab product (such as Inflectra). It is a subcutaneous (SC) injection that people can self-administer at home.
Cabtreo
Oct 24, 2023 - Cabtreo is a triple combination topical gel that contains clindamycin phosphate, adapalene, and benzoyl peroxide and may be used to treat acne in adults and children aged 12 and older.
Tofidence
Oct 2, 2023 - Tofidence (tocilizumab-bavi) is administered as an intravenous infusion by a healthcare provider and may be used to treat patients who meet certain criteria with rheumatoid arthritis, or polyarticular or systemic juvenile idiopathic arthritis. Tofidence is a biosimilar to Actemra (tocilizumab).
Pombiliti
Sep 29, 2023 - Pombiliti (cipaglucosidase alfa-agta) is an intravenous infusion that is given over approximately 4 hours by a healthcare provider in combination with oral Opfolda (miglustat) capsules (an enzyme stabilizer) for the treatment of adult patients with late-onset Pompe disease, who weigh at least 40kg (88 lb) and who are not improving on their current enzyme replacement therapy (ERT).
Likmez
Sep 27, 2023 - Likmez is a ready-to-use liquid suspension of metronidazole, which is an antibiotic that may be used to treat trichomoniasis and anaerobic bacterial infections in adults, and amebiasis in adults and children. Likmez does not need refrigeration and the suspension is a strawberry-peppermint flavor. The strength is 500mg/5ml.
Ojjaara
Sep 18, 2023 - Ojjaara (momelotinib) is a Janus kinase inhibitor that may be used to treat intermediate or high-risk myelofibrosis (MF) in adults with anemia.
Tyruko
Aug 25, 2023 - Tyruko (natalizumab-sztn) is an injectable integrin receptor antagonist that is a biosimilar to Tysabri (natalizumab), that may be used to treat adults with relapsing forms of multiple sclerosis or moderate to severe Crohn's disease (usually after other treatments have been tried).
Bylvay
Aug 24, 2023 - Bylvay (odevixibat) is an oral capsule that may be used to treat itching (pruritus) caused by progressive familial intrahepatic cholestasis (PFIC; a genetic disorder) in adults and children 3 months of age and older. It may also be used to treat cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS).
Xdemvy
Jul 26, 2023 - Xdemvy (lotilaner 0.25% ophthalmic) is an anti-parasitic eye drop solution that may be used to treat Demodex blepharitis in adults 18 years of age and older.
Cyfendus
Jul 25, 2023 - Cyfendus (anthrax vaccine adsorbed, adjuvanted) is a vaccine indicated for the post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons aged 18 through 65 years of age. It is administered in conjunction with recommended antibacterial drugs.
Ycanth
Jul 23, 2023 - Ycanth (cantharidin 0.7%) is a topical solution that is applied by a healthcare provider once every 3 weeks to the skin as needed to treat molluscum contagiosum in adults and children 2 years of age and older.
Beyfortus
Jul 18, 2023 - Beyfortus (nirsevimab-alip) is a long-acting monoclonal antibody with activity against the respiratory syncytial virus (RSV) that may be used to protect neonates and infants against lower respiratory tract disease (LRTD) caused by RSV.
Roctavian
Jul 2, 2023 - Roctavian (valoctocogene roxaparvovec-rvox) is a single-dose gene therapy infusion that may be used to treat adults with severe hemophilia A who have had a blood test to determine they do not have antibodies to a particular adenovirus serotype, AAV5.
Lantidra
Jun 30, 2023 - Lantidra (donislecel-jujn) is an allogeneic pancreatic islet cellular therapy for the treatment of type 1 diabetes mellitus in adults whose symptoms are not well controlled.
Ngenla
Jun 29, 2023 - Ngenla may decrease insulin sensitivity and cause high blood sugar levels. Glucose levels should be monitored periodically in all patients, especially those with existing diabetes mellitus or at risk for its development.
Rystiggo
Jun 28, 2023 - Rystiggo (rozanolixizumab-noli) is a subcutaneous (under the skin) infusion that may be used to improve muscle weakness in adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Vyvgart Hytrulo
Jun 28, 2023 - Vyvgart Hytrulo is a combination subcutaneous infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with generalized myasthenia gravis who are anti-AChR antibody positive.
Suflave
Jun 28, 2023 - Suflave is a combination, osmotic prescription laxative that may be used to cleanse the bowel in preparation for colonoscopy in adults. Suflave contains polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride, and is supplied as a powder that is mixed with a low volume of water before consuming. It tastes like a lemon-lime sports drink.
Litfulo
Jun 27, 2023 - Litfulo (ritlecitinib) is an oral, once-daily prescription treatment for severe alopecia areata in adults and adolescents aged 12 and older.
Columvi
Jun 16, 2023 - Columvi (glofitamab-gxbm) is an immunotherapy treatment that may be used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Vevye
Jun 15, 2023 - Vevye is a solution of cyclosporine 0.1% that may be used in the eyes to treat the signs and symptoms of dry eye disease. It is supplied as eye drops.
Inpefa
May 29, 2023 - Inpefa (sotagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure, or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
Epkinly
May 22, 2023 - Epkinly (epcoritamab-bysp) is a bispecific CD20-directed CD3 T-cell engager for use in the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Miebo
May 20, 2023 - Miebo (perfluorohexyloctane) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease.
Lumryz
May 16, 2023 - Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate indicated for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Abilify Asimtufii
May 16, 2023 - Abilify Asimtufii (aripiprazole) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder.
Veozah
May 15, 2023 - Veozah (fezolinetant) is a selective neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Vowst
May 3, 2023 - Vowst (fecal microbiota spores, live-brpk) is an oral microbiome therapeutic indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI.
RizaFilm
Apr 18, 2023 - RizaFilm (rizatriptan) is a serotonin (5-HT) 1B/1D receptor agonist (triptan) oral film formulation for the acute treatment of migraine.
Joenja
Mar 28, 2023 - Joenja (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
Rezzayo
Mar 27, 2023 - Rezzayo (rezafungin) is an echinocandin antifungal used for the treatment of candidemia and invasive candidiasis.
Zynyz
Mar 22, 2023 - Zynyz (retifanlimab-dlwr) is a programmed death receptor-1 (PD-1)-blocking antibody for the treatment of Merkel cell carcinoma.
Daybue
Mar 14, 2023 - Daybue (trofinetide) is a synthetic analog of the amino‐terminal tripeptide of IGF-1 for the treatment of Rett syndrome.
Zavzpret
Mar 13, 2023 - Zavzpret (zavegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine.
Combogesic
Mar 5, 2023 - Combogesic (acetaminophen and ibuprofen) is a combination prescription medicine used for the management of mild to moderate acute pain.
Skyclarys
Mar 2, 2023 - Skyclarys (omaveloxolone) is an activator of Nrf2 (nuclear factor erythroid 2–related factor 2) for the treatment of Friedreich’s ataxia.
Filspari
Feb 20, 2023 - Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
Jaypirca
Feb 1, 2023 - Jaypirca (pirtobrutinib) is an oral kinase inhibitor that is approved under the accelerated approval classification to treat adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of treatment, including a BTK inhibitor, and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two lines of treatment, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor.
Brenzavvy
Jan 23, 2023 - Brenzavvy (bexagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Briumvi
Jan 16, 2023 - Briumvi (ublituximab-xiiy) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
Airsupra
Jan 13, 2023 - Airsupra (albuterol and budesonide) is a beta2-adrenergic agonist and corticosteroid fixed-dose combination rescue inhaler for as-needed use to reduce the risk of asthma exacerbations.
Leqembi
Jan 6, 2023 - Leqembi (lecanemab) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease.
Lunsumio
Jan 6, 2023 - Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager for the treatment of relapsed or refractory follicular lymphoma.